Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality

BACKGROUND: The US Food and Drug Administration authorized COVID-19 convalescent plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:eLife
Päätekijät: Casadevall, Arturo, Dragotakes, Quigly, Johnson, Patrick W, Senefeld, Jonathon W, Klassen, Stephen A, Wright, R Scott, Joyner, Michael J, Paneth, Nigel, Carter, Rickey E
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: eLife Sciences Publications, Ltd 2021
Aiheet:
Epidemiology and Global Health
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8205484/
https://ncbi.nlm.nih.gov/pubmed/34085928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.69866
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia